BioMarin Announces Third Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall Street ends down as expectations of Hormuz deal fade
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil climbs 5% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $99 at RBC Capital
October 26, 2018 7:09 AM EDTRBC Capital analyst Kennen MacKay raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $99.00 (from $98.00) while maintaining a Sector Perform rating following results.
The analyst notes strong Q3 with top/bottom line beats and tantalizing hints at pipeline updates at the upcoming Nov7 RnD Day.
... More
BioMarin Pharma (BMRN) Tops Q3 EPS by 15c, Offers Guidance
October 25, 2018 4:10 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.07), $0.15 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $391.7 million versus the consensus estimate of $367.09 million.
GUIDANCE:
BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion, versus the consensus of... More
